Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Programmed cell death in human breast cancer cells

D E McCloskey1, D K Armstrong, C Jackisch

  • 1Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA.

Recent Progress in Hormone Research
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

ESMO open·2025
Same author

Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study.

ESMO open·2025
Same author

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

[Predictive molecular diagnostics in breast cancer : What are the requirements for pathology today and in the future?]

Pathologie (Heidelberg, Germany)·2022
Same author

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Targeting programmed cell death pathways offers a promising strategy for improving systemic therapy in breast cancer. Research explores harnessing these natural cell death mechanisms to combat cancer growth effectively.

Area of Science:

  • Oncology
  • Cell Biology
  • Cancer Therapeutics

Background:

  • Breast cancer treatment necessitates novel systemic therapies due to complex growth dynamics.
  • Cancer progression involves an imbalance between cellular proliferation and programmed cell death.
  • Understanding cell death pathways is crucial for developing effective anti-cancer strategies.

Purpose of the Study:

  • To review the role of programmed cell death in normal mammary tissue homeostasis.
  • To examine the preservation and exploitation of cell death pathways in breast cancer.
  • To explore novel clinical applications targeting programmed cell death.

Main Methods:

  • Literature review focusing on programmed cell death mechanisms in mammary tissues.
  • Analysis of chemotherapeutic agent efficacy in inducing programmed cell death in cancer cells.

Related Experiment Videos

  • Examination of current research on clinical strategies targeting cell death pathways.

    • Main Results:

    • Programmed cell death is vital for maintaining normal mammary tissue balance.
    • Malignant mammary cells often retain susceptibility to programmed cell death induction.
    • Chemotherapeutic agents can initiate programmed cell death in breast cancer cells.

    Conclusions:

    • Targeting programmed cell death pathways represents a significant therapeutic avenue for breast cancer.
    • Further research into clinical applications of these pathways holds promise for improved patient outcomes.
    • Harnessing cell death mechanisms offers a strategy to re-sensitize resistant cancer cells.